Gazyva Injection, Solution, Concentrate
Product Images NDC 50242-070

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Gazyva (NDC 50242-070). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Genentech, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Gazyva 01)

A survival curve graph comparing overall survival over time in months between two treatment groups: Clb and G-Clb. The graph shows Kaplan-Meier survival estimates, with lines representing each group, and includes hazard ratio with 95% confidence interval, number of patients at risk over time, and median survival time not reached for both groups.*

FDA Label Image

Figure 2 (Gazyva 02)

A Kaplan-Meier curve depicting progression-free survival (PFS) over time (months) comparing two treatment groups, G-Clb and R-Clb. The graph shows survival probabilities declining over 39 months, with G-Clb demonstrating higher PFS. Median PFS times, hazard ratio, confidence interval, and log-rank p-value are provided along with numbers at risk at various time points.*

FDA Label Image

Figure 3 (Gazyva 03)

A Kaplan-Meier survival curve comparing the probability of progression-free survival (PFS) over time (months) between patients treated with Gazyva plus bendamustine and those treated with bendamustine alone. The graph shows PFS probabilities on the vertical axis and time in months on the horizontal axis, with patient numbers at risk listed beneath. The plot includes median time data and hazard ratio statistics comparing the two groups.*

FDA Label Image

Figure 4 (Gazyva 04)

Kaplan-Meier survival curve graph depicting the probability of overall survival (OS) over time in months, comparing Bendamustine alone (solid line) and Gazyva plus Bendamustine (dashed line) in patient groups. The graph includes median survival times, hazard ratio, confidence interval, p-value, and number of patients at risk at various time points.*

FDA Label Image

Figure 5 (Gazyva 05)

A Kaplan-Meier survival curve chart showing the probability of progression-free survival (PFS) over time in months for two treatment groups: R-chemo (rituximab plus chemotherapy) and G-chemo (obinutuzumab plus chemotherapy). The graph includes numbers at risk, confidence intervals, hazard ratios, and a stratified log-rank p-value comparing the two groups.*

FDA Label Image

Principal Display Panel (40 mL Vial Carton)

Label for Gazyva (obinutuzumab) injection, 1000 mg/40 mL (25 mg/mL) concentrate for intravenous infusion. The label indicates this is a single-dose vial with no preservative and instructs discard of unused portion. The product is labeled by Genentech, Inc., with NDC 50242-070-01 and is for prescription use only.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.